Jeito Capital becomes key investor in Alentis Therapeutics
Jeito Capital Becomes Key Investor in Alentis Therapeutics in $ 67 Million Series B Funding Round
- Jeito Capital selects Alentis Therapeutics as its fifth investment since the launch of the fund
- Alentis focuses on the development of disruptive treatments for fibrotic diseases and associated cancers
Paris, Francid, 15 June 2021 – Jeito Capital (“Jeito“), a growing independent biotechnology and biopharma private equity firm, today announces that it has become a key investor in a $ 67 million Series B financing round in Alentis Therapeutics (Alentis). The Swiss biotechnology company, a spin-off of French Inserm with R&D in Strasbourg, France, is developing disruptive therapies for patients with fibrotic diseases and associated cancers.
The proceeds from the funding round will be used for proof-of-concept clinical trials of Alentis first-in-class actives, targeting only the fibrosis pathways for the treatment of life-threatening advanced hepatic and renal fibrosis as well as cancers. associates. Alentis plans to launch its first clinical trial by the end of 2021.
Jeito’s investment aims to enable Alentis to accelerate the clinical journey for a variety of indications, with the potential to provide life-changing treatments for critically ill patients who have no other options. The investment will also give the Company the opportunity to expand its pipeline and explore other indications, including cancers associated with fibrosis.
The round table brings together Jeito Capital and Morningside Venture Investments alongside existing investors BioMed Partners, BB Pureos Bioventures, Bpifrance, High-Tech Gründerfonds and Schroders Capital. Following the fundraising, Rafaèle Tordjman, Founder and CEO of Jeito Capital, will join the Board of Directors of Alentis.
This is Jeito’s fifth investment since the launch of its fund in 2020. With more than € 250 million under management, Jeito Capital is building a strong and diversified portfolio of biotechnology and biopharmaceutical companies based in Europe with a global reach focused on the treatment of fatal diseases. . Previous investments include French companies SparingVision and InnoSkel, respectively in ophthalmology and rare skeletal disorders, Dutch biotech Neogen Therapeutics in solid tumors, and recently Pulmocide in respiratory diseases, based in the UK.
Alentis is led by a highly experienced management team drawn from the biotechnology and pharmaceutical industries. The science of the Company is based on more than 10 years of research by founder Thomas Baumert, a world-class hepatology expert who currently heads the Institute of Viral and Hepatic Diseases at Inserm. Professor Baumert’s research on Claudin-1 is unique and, so far, has not been explored as a potential therapeutic target for fibrotic diseases.
Rafaèle Tordjman, founder and CEO of Jeito, said: “Our investment in Alentis in this pivotal period of development will be crucial for his success and we are eager to work closely to the sides theI very experienced team. Our expertise lies in help management teams from science to commercialization of the product and here we will aim to accelerate ‘Alentis’ efforts to launch the vsthe company’s first clinical trials. This represents our fifth investment in our diversified portfolio and strengthens our commitment at invest in European biotechs working to develop life–save assets targeted on diseases with unmet needs based on exceptional science.“
rer. Roberto Iacone, general manager of Alentis Therapeutics, mentionned: “We are delighted having closed this round table with new investors Jeito Capital and Morningside Venture Investments, two respectsd and highly competent institutions within the healthcare space that will provide valuable Board experience as we move towards launching our first clinical trials. Build on 20 years of work and positive preclinical data collected on ALE.F02, we are confident in the success of future trials as we work with both new and existing investors towards marketing, provideis lying a much needed safe and effective treatment to the sick suffer from fibrotic diseases and hepatobiliary cancers. “
About Jeito Capital
Jeito Capital is a world leading investment firm with a patient benefits approach that funds and accelerates breakthrough medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated and versatile team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated access to patients in Europe and the United States. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit www.jeito.life, or follow on Twitter @Jeito_life or LinkedIn.
About Alentis Therapeutics
Alentis Therapeutics is a Swiss-based biotechnology focused on the development of breakthrough treatments for fibrotic diseases. The company was founded in 2019 on the basis of innovative research carried out in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and at the National Institute of Health (Inserm).
The company’s main candidates are highly selective monoclonal antibodies for Claudin-1, a new untapped target with a unique mechanism of action that plays a key role in the pathology of hepatic fibrosis and fibrosis-induced hepatobiliary cancers. He also has early discovery programs exploring the potential of Claudin-1 inhibition in the treatment of fibrosis in other tissues, including the kidney and lung. These represent very large and expanding markets with high unmet needs. In addition, the company uses a patient-derived drug and target discovery platform to develop drugs for advanced fibrosis.
Unlike current fibrosis therapies, which primarily treat the disease indirectly, Alentis’ pioneering approach has the potential to directly alter and reverse the course of disease progression.
Alentis is headquartered in the pharmaceutical and biotechnology center in Basel, Switzerland with a subsidiary for R&D in Strasbourg, France.
For more information, visit https://alentis.ch/
For more information please contact:
Rafaèle Tordjman, Founder and CEO
Strategic communication of the Consilium
Mary-Jane Elliott / Melissa Gardiner / Davide Salvi / Kris Lam
|Phone: + 33 (0) 6 35 36 35 00
Phone: +44 (0) 20 3709 5700